» Articles » PMID: 32739782

Chronic Fatigue in Myelodysplastic Syndromes: Looking Beyond Anemia

Overview
Specialty Hematology
Date 2020 Aug 3
PMID 32739782
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic fatigue is the most common and severe symptom in myelodysplastic syndromes (MDS) and has a strong negative association with health-related quality of life (HRQoL). Despite anemia being the most common objective manifestation of MDS, and the associated link between anemia and fatigue, evidence on treatments which temporarily mitigate anemia is equivocal regarding the effects on fatigue. Furthermore, previous work has found weak associations between anemia and chronic fatigue in MDS. As such, given that improving HRQoL is one of the primary treatment aims in MDS, further work is required to identify other potential contributors to chronic fatigue in these patients. In addition to anemia, MDS is associated with numerous other deviations in physiological homeostasis and has negative psychological consequences with links to chronic fatigue. Accordingly, the present review provides several potential aetiologic agents relevant to chronic fatigue in MDS which can be used to guide future research in this field.

Citing Articles

Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.

Thalambedu N, Mohan Lal B, Harbaugh B, Alapat D, Gaddam M, Gentille Sanchez C Cancers (Basel). 2025; 17(3).

PMID: 39941875 PMC: 11816122. DOI: 10.3390/cancers17030508.


Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy.

Shen B, Luo F, Yuan N, Yin J, Chai Y, Sun L Open Med (Wars). 2024; 19(1):20241009.

PMID: 39221033 PMC: 11365463. DOI: 10.1515/med-2024-1009.


Hemoglobin and Its Relationship with Fatigue in Long-COVID Patients Three to Six Months after SARS-CoV-2 Infection.

Bazdar S, Bloemsma L, Baalbaki N, Blankestijn J, Cornelissen M, Beijers R Biomedicines. 2024; 12(6).

PMID: 38927441 PMC: 11201257. DOI: 10.3390/biomedicines12061234.


Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace F, Buckstein R, Abel G, Giesinger J, Fenaux P, Bewersdorf J Hemasphere. 2024; 8(5):e69.

PMID: 38774655 PMC: 11106800. DOI: 10.1002/hem3.69.


Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.

Giesinger J, La Nasa G, Sparano F, Angermeyer M, Morelli E, Mulas O Clin Pract Epidemiol Ment Health. 2022; 17(1):307-314.

PMID: 35444708 PMC: 8985474. DOI: 10.2174/1745017902117010307.